In 2025, Russian enterprises have launched full-cycle production of several generics of imported drugs for cancer prevention, Anton Alikhanov, Minister of Industry and Trade, said at the government hour in the Federation Council. His words were quoted by the Parliamentary Newspaper.
“Since the beginning of 2025, domestic enterprises have only mastered the full production cycle of several analogues of imported drugs for preventing cancer. In the future, we also expect new Russian innovative drugs for cardiovascular diseases and diabetes,” Alikhanov said.
The head of the Ministry of Industry and Trade added that Russia continues to develop radiopharmaceuticals, a priority area with market share already exceeding 90% in natural units.
Alikhanov recalled that by 2030 it is planned to increase the supply of raw materials to the Russian pharmaceutical industry to 80%. First of all, this concerns strategically important medicines. A total of 186 names of drugs is included in the plan.
Earlier, it was announced that the Ministry of Industry and Trade had presented the final version of its approach to forming the list of strategically important medicines to the industry. The list will be divided into two groups with different support measures: the first group will follow the “second-one-out” rule, while the medicines of the second list will receive only price preferences. The industry as a whole supported this approach.
